Snowden Capital Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Snowden Capital Advisors’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,984	Closed	-$27K	–	1949
2021 Q4	$27K	Buy	+1,984	New	+$27.8K	﹤0.01%	1226

Other funds holding TAK

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Snowden Capital Advisors's TAK Position: Q1 2022 in Review

Snowden Capital Advisors sold out of Takeda Pharmaceutical (TAK) in Q1 2022, closing a stake of 1,984 shares — an estimated $27K sold.

Snowden Capital Advisors first reported a position in TAK in Q4 2021 and held it in 1 quarter. The position peaked at $27K in Q4 2021. 288 funds tracked by Wall St. Rank hold TAK as of Q1 2022.

Snowden Capital Advisors reported no remaining Takeda Pharmaceutical position as of Q1 2022 after selling out during the quarter.
Snowden Capital Advisors sold 1,984 Takeda Pharmaceutical shares in Q1 2022, an estimated $27K.
Snowden Capital Advisors first reported a position in Takeda Pharmaceutical in Q4 2021 and held it in 1 quarter.
Snowden Capital Advisors's Takeda Pharmaceutical position peaked at $27K in Q4 2021.
288 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.